Highlights from our 2023 Impact Report – a look at Pfizer’s Environmental Social and Governance Performance 

March 18, 2024
 
As Pfizer celebrates 175 years of scientific innovation, we continue channeling our passion and resources into delivering innovative therapies that are helping to change the face of healthcare. Pfizer prioritizes the health and well-being of people and the planet to deliver our medicines and vaccines around the world in a responsible way.  
 
Recently, Pfizer published its Impact Report, providing an overview of Pfizer’s Environmental, Social and Governance (ESG) priorities and goals, aimed at contributing to long-term value creation and a sustainable, responsible, and patient-centric business model aligned to our purpose. 
 
According to Pfizer’s Chairman and CEO Albert Bourla, the Impact Report “reflects our dedication to being a force for good in the world by acting with integrity, holding ourselves to high standards, being accountable to our commitments, and addressing shortcomings candidly and with specific plans for improvement.” 

Our Approach to ESG 
 
As we reflect on 2023, we take pride in the positive impact our scientific discoveries continue to have on patients and global health. However, the challenges facing our society demand agility and a constant drive to do more. By remaining focused on our purpose, we believe we can continue to have a significant positive impact on human health.   
 
We apply science and our global resources to bring therapies to people that contribute to improving health outcomes through the discovery, development, and manufacturing of medicines and vaccines.  

With collaboration at all levels, we aim to build trust, create shared value, and make a positive impact on society for years to come. 

Here are our ESG priorities, as stated in the report: 

• Product innovation: Reducing cycle times, increasing success rates, and getting more innovative medicines into the hands of patients sooner. 

• Climate change: Taking action to reduce our greenhouse gas emissions and mitigate risks associated with a changing climate. 

• Equitable access and pricing: Expanding affordable access to our medicines and vaccines, and protecting people from the burden of infectious and other diseases. 

• Product quality and safety: Maintaining a quality culture to ensure the highest priority is placed on the safety, efficacy, and reliability of our products, the safety of our patients and consumers, the quality of data supporting regulatory submissions, and interactions with our stakeholders. 

• Diversity, equity, and inclusion: Creating opportunities to advance diversity, equity, and inclusion across our workforce, those with whom we do business, and society at large. 

• Business ethics: Exercising strong corporate governance and risk management practices to promote the long-term interests of our stakeholders. 

“Pfizer’s track record in the environmental, social and governance (ESG) space is strong,” says Dr. Bourla. “We look forward to continuing to build on it.” 

Here are some global highlights from our 2023 Impact Report: